With reference to the National Pharmaceutical Pricing Authority (NPPA) and anti-cancer medicine pricing, consider the following statements: 1. The revised MRPs for anti-cancer brands become effective on November 9, 2025. 2. The NPPA released revised MRPs for 543 anti-cancer medicine brands. 3. Trade Margin Rationalisation was conducted for 137 non-scheduled drugs. Which of the statements given above is/are correct?

JSA India criticizes NPPA's flawed formula for revised MRPs of 543 anti-cancer brands

GS2Polity · Governance · IR· Health policy & public health· Prelims + Mains· 28 October 2026

Pharmaceutical price regulation and affordability: a GS2 Social Justice and Public Health case study.

Why in news

JSA India criticized the NPPA's flawed formula and lack of independent verification for revised MRPs of 543 anti-cancer medicine brands.

Background

The NPPA released revised MRPs for 543 anti-cancer medicine brands effective November 9, 2026. This followed a Trade Margin Rationalisation of 137 non-scheduled drugs on October 17, 2026.

Facts for Prelims

BodyNPPA: National Pharmaceutical Pricing Authority
Fact543 anti-cancer medicine brands received revised MRPs
Fact137 non-scheduled drugs underwent Trade Margin Rationalisation on October 17, 2026
FactRevised MRPs for anti-cancer brands become effective on November 9, 2026

Prelims practice question

With reference to the National Pharmaceutical Pricing Authority (NPPA) and anti-cancer medicine pricing, consider the following statements:

The revised MRPs for anti-cancer brands become effective on November 9, 2025.
The NPPA released revised MRPs for 543 anti-cancer medicine brands.
Trade Margin Rationalisation was conducted for 137 non-scheduled drugs.

Which of the statements given above is/are correct?

(a)1 only
(b)1 and 2 only
(c)1 and 3 only
(d)2 and 3 only

Show answer

Answer: (d) 2 and 3 only — Statements 2 and 3 are correct. Statement 1 is incorrect: The note states the effective date is November 9, 2026.

For Mains

Q. Critically examine the challenges in balancing pharmaceutical affordability with industry viability in India's healthcare sector.

Dimensions to cover in your answer

Regulatory oversight: Lack of independent verification in NPPA's price revision formulas
Access to medicine: Impact of flawed pricing models on treatment continuity for chronic illnesses
Market distortion: Trade Margin Rationalisation effects on non-scheduled drug availability

Keywords: Affordability · Regulatory Framework · Price Control · Public Health · Market Rationalisation

Read the full news →Report a mistake in this note How notes are made Source: The Hindu ↗Also: GS3 · Industry, investment & MSMEs

More Social Justice notes

Union Cabinet approves ₹7,395.55-crore PM-VGSY scheme to train 32 lakh representatives · 28 October 2026
Supreme Court grants OBC Federation liberty to petition for Census 2027 drop-down menu · 28 October 2026
Pralhad Joshi slams "marks wadi" education system at new CBSE Experience Centre · 28 October 2026
Supreme Court questions NPPA after only ₹1,582.4 crore recovered from overcharging companies · 27 October 2026
Kerala government considers ‘Academic Election Commission’ to reform student union elections · 27 October 2026
Karnataka to establish first Tribal University on 120 acres in Challakere taluk · 27 October 2026

All Social Justice current affairs →

Something wrong, or something missing?

Spotted a mistake in a note, or want a topic, format or PDF that would help your preparation? Write to us. We read every mail and fix errors fast.

Report a mistake →Ask for something →[email protected]

This note is generated automatically from SatyaDheesh's news feed and mapped to the UPSC CSE syllabus. Check facts against the original report or PIB before using them in an answer.